EBF3 and glioma: To evaluate DNA methylation changes in both the promoter and gene body of EBF3 and TBC1D16, we interrogated all analysed CpG sites in independent whole genome bisulfite sequencing (WGBS) data [18] derived from five different normal tissues/cell lines (B cells, lung, brain, breast and colon), six different primary tumours/cell lines (small cell lung carcinoma, squamous cell carcinoma of the lung, adenocarcinoma of the lung, glioma, primary breast cancer, primary colorectal cancer) and metastases (breast, colorectal) (Fig. 4).